Frontline Pembrolizumab Improves Health-Related QOL in DNA Repair-Deficient Metastatic CRC
September 19, 2020

Frontline pembrolizumab induced clinically meaningful improvements in the health-related quality of life of patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer.

Durvalumab Monotherapy, Combination Fail to Improved OS in Metastatic Urothelial Carcinoma
September 19, 2020

Durvalumab, with or without tremelimumab, failed to meet its primary end point of overall survival in patients with metastatic urothelial cancer.

Ipi-Nivo Combination Yields Improved Responses After 4-Year Follow-Up in Advanced RCC
September 19, 2020

The combination use of nivolumab plus ipilimumab, compared with sunitinib, continued to show benefit during a 4-year follow-up in patients with advanced renal cell carcinoma.

PD-L1 Expression May Be Associated with Pathological Complete Response in TNBC
September 19, 2020

“PD-L1 expression was significantly associated with pCR, which increased with higher PD-L1 expression on immune cells,” said Giampaolo Bianchini, an author of the NeoTRIPaPDL1 study.

Study Supports Nivolumab/Cabozantinib as Frontline Option in Advanced Renal Cell Carcinoma
September 19, 2020

“With expanding options for patients with advanced RCC, the overall efficacy, safety, and quality of life benefits, as well as individual patient characteristics, are very important considerations when you select appropriate therapy.”

Xevinapant Plus CRT Improves Survival in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
September 19, 2020

The first-in-class inhibitor of apoptosis protein (IAP) antagonist significantly improved overall survival in patients with LA-SCCHN.